[Epidemic trends and prevention and control of seasonal influenza in China after the COVID-19 pandemic].

During the COVID-19 pandemic, a series of non-pharmaceutical interventions, which were implemented to curb the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), significantly modified the seasonal pattern of influenza. The intensity of influenza activity markedly decreased and B/Yamagata lineage was no longer detected. As the national influenza sentinel surveillance data shown, clear seasonal patterns were observed for influenza between 2012-2019, annually with an average of 14.57% of specimens tested positive for influenza virus. However, the seasonal pattern of influenza was disrupted after the outbreak of COVID-19. In the 2020-2021 season, influenza demonstrated an extremely low activity (yearly positivity rate<1.0%), followed by a resurgence of winter peak in the 2021-2022 season. Following the downgrade of management of COVID-19 to Class B in China in December 26, 2022, social activities gradually resumed, leading to the rebound of influenza activity with an out-of-season ciculation. After COVID-19 pademic, other respiratory infectious diseases caused by SARS-CoV-2, respiratory syncytial virus, and mycoplasma pneumonia were alternatively or concurrently circulated with influenza. The prevention and control of influenza and other respiratory infectious diseases emphasizes a multi-disease prevention strategy, including long-term and continuous monitoring the epidemic trends in influenza virus and SARS-CoV-2, promoting influenza and COVID-19 vaccination among key populations, and strengthening the knowledge and public awareness of prevention and control for respiratory infectious diseases, etc.

[Reflections on the positioning and implementation pathways of adult vaccine prescriptions].

The innovation of integrating medical treatment and prevention mechanisms is a key task deployed by the government, aiming to promote the construction of a Healthy China and address the prevalent "treatment over prevention" mindset in healthcare services and society. Vaccination is an effective strategy for preventing and controlling infectious diseases; however, adult vaccination rates in China remain low due to insufficient awareness and enthusiasm among the public and healthcare professionals. In recent years, various regions have begun to explore the model of physicians in medical institutions prescribing vaccines to improve vaccination rates. This article analyzes the positioning, current implementation status, and challenges of vaccine prescriptions, and proposes recommendations advocating policy formulation, improving service models and supporting measures, improving funding mechanisms, and strengthening publicity and education to promote the widespread implementation and effectiveness of vaccine prescriptions.

[The international cases of vaccinology education and its enlightenment to the discipline development in China].

Vaccination is an effective public health measure to prevent and control vaccine-preventable diseases for individual and society. However, China currently confronts significant challenges, including a dearth of skilled professionals in the field of vaccination and disparities in the capacity for immunization services. This review introduced the experiences of four prime international vaccinology education models, including London School of Hygiene & Tropical Medicine, Johns Hopkins University, Leading International Vaccinology Education, and the Bill & Melinda Gates Foundation, in the aspect of personnel development, academic research and communication platforms establishment. It is supposed to give some insights and feasible suggestions on the establishment and advancement of vaccinology as a sub-discipline within high-level public health school in China, with the aim of development of a robust vaccinology education framework in China, which is essential for nurturing the next generation of public health leaders and practitioners for our country.

[Influencing factors of hypertension and diabetes care cascade: a qualitative study].

Objective: Employing the cascade care model, this qualitative study explores determinants influencing the cascading care stages of hypertension and diabetes by interviewing various stakeholders. Methods: In July 2023, purposive sampling was employed to recruit participants from Gongyi and Wugang cities in Henan Province, and Linqu County in Weifang City, Shandong Province. Semi-structured in-depth interviews were conducted with representatives of policymakers, healthcare institution managers, providers, and patients with hypertension and diabetes.And thematic analysis was performed using both inductive and deductive approaches. Results: A total of 82 individuals were interviewed, with an age range of (53.8±12.0) years, among which 48 (58.5%) were male; including 5 policymakers, 10 institutional managers, 20 healthcare providers, and 47 patients with hypertension and diabetes. The study identified both barriers and facilitating factors at the patient, healthcare provider, and system levels across various stages: awareness, screening, diagnosis, treatment, long-term management, and control of hypertension and diabetes. Conclusion: By delineating and analyzing the barriers and facilitators at each stage of hypertension and diabetes care, this study lays the groundwork for the development of effective, feasible, and sustainable implementation pathways, with significant implications for the enhanced management of hypertension and diabetes in China.

[The value of vaccines from the perspective of population medicine].

Vaccination is one of the most effective, broad-reach, and cost-effective public health initiatives to fight against infectious diseases. From the perspective of population medicine, this article systematically elaborates on the value of vaccines in preventing infections, reducing disease incidence, decreasing disability and severe cases, lowering mortality rates, improving population health and life expectancy, reducing antibiotic use and resistance, as well as promoting fairness in public health services. Based on the current situation, the following recommendations are proposed: first, strengthen scientific research to provide a solid foundation for related policy-making; second, increase the coverage rate of non-national immunization program vaccines; third, promote the inclusion of more appropriate vaccines in the national immunization program; fourth, strengthen the research and development of new vaccines; and fifth, increase talent training in the field of vaccinology.

[Consideration on the usage of full-dose influenza vaccine for the infants aged 6-35 months old].

Seasonal influenza has a high disease burden, and children infected with influenza are prone to multiple complications. Influenza vaccination is effective in preventing infection and reducing risks of severe diseases and complications. Influenza vaccines are trivalent and quadrivalent, depending on the components of the vaccine. According to the hemagglutinin content, it can be divided into full dose and half dose of influenza vaccine for children. The findings from clinical trials and real-world studies suggested, the full-dose influenza vaccine as in adults has the same safety profile and higher immunogenicity in children aged 6 to 35 months. The application of full-dose influenza vaccine in children aged 6 to 35 months can greatly improve the flexibility and convenience of vaccination, and help reduce the workload in the process.

[Clinical research progress of human respiratory syncytial virus vaccine].

Human respiratory syncytial virus (HRSV) is one of the main pathogen causing severe acute lower respiratory tract infections in infants and the elderly, with high incidence rate and mortality worldwide. Vaccine is one of the important measure to prevent infection, transmission and severe disease of HRSV, but currently there is no officially approved preventive vaccine for prevention of HRSV in the world. This paper reviews and analyzes the current research and development progress of HRSV vaccine, summarizes the design routes of different types of HRSV preventive vaccines, and discusses the difficulties and challenges in vaccine research and development, in order to provide reference for the research and development of HRSV vaccine and the development of clinical trials.

[Establishing adult vaccination system to improve the quality of immunization services over the life course].

The scientific setting and standardized management of adult vaccination clinics will improve the accessibility of vaccination services, thereby increasing the vaccination rate. Currently, some provinces and cities in China have been exploring the construction of adult vaccination systems for many years, effectively improving the level of vaccination services, and forming some useful experiences and models. However, the construction of China's adult vaccination system is not yet perfect, and the service mode needs to be optimized. In the future, we should continue to improve the guarantee measures for adult vaccination, scientifically lay out the network, optimize the service mode, and improve the overall quality of immunization services over the life course.

[Research progress on the burden of respiratory syncytial virus infection in the elderly].

Human Respiratory Syncytial Virus (HRSV) is a serious threat to the population health. The elderly are one of the susceptible populations. The prevalence of HRSV in the elderly is generally higher than that in other age groups except children, which has gradually attracted attention in recent years. This paper reviewed the prevalence, common complications and major complications of HRSV in the elderly, briefly expounded the economic burden of HRSV infection, and proposed that attention should be paid to the disease burden of the elderly after HRSV infection, timely treat common complications, so as to reduce the occurrence of adverse survival outcomes and provide scientific evidence for the prevention and control of HRSV infection in the elderly.

[Research and reflection on the diversified method system of multi-stages and multi-scenarios surveillance and early warning of infectious diseases].

With the outbreak of infectious diseases, more and more attention has been paid to surveillance and early warning work. Timely and accurate monitoring data is the basis of infectious diseases prevention and control. Effective early warning methods for infectious diseases can improve the timeliness and sensitivity of early warning work. This paper briefly introduces the intelligent early warning model of infectious diseases, summarizes the emerging surveillance and early warning methods of infectious diseases, and seeks the possibility of diversified surveillance and early warning in different epidemic stages and different outbreak scenarios of infectious diseases. This paper puts forward the idea of constructing a diversified method system of infectious diseases surveillance and early warning based on multi-stages and multi-scenarios and discusses the future development trend of infectious diseases surveillance and early warning, in order to provide reference for improving the construction level of infectious diseases surveillance and early warning system in China.

[Introduction and implications of WHO position paper: vaccines against influenza, May 2022].

On May 13, 2022, World Health Organization(WHO) Position Paper on Influenza Vaccine (2022 edition) was published. This position paper updates information on influenza epidemiology, high risk population, the impact of immunization on disease, influenza vaccines and effectiveness and safety, and propose WHO's position and recommendation that all countries should consider implementing seasonal influenza vaccine immunization programmes to prepare for an influenza pandemic. In addition, it proposes that the influenza surveillance platform can be integrated with the surveillance of other respiratory viruses, such as SARS-CoV-2 and Respiratory Syncytial Virus. This position paper has some implications for the prevention and control of influenza and other respiratory infectious diseases in China: (1) Optimize influenza vaccine policies to facilitate the implementation of immunization services; (2) Influenza prevention and control should from the perspective of Population Medicine focus on the individual and community to integrate with "Promotion, Prevention, Diagnosis, Control, Treatment, Rehabilitation"; (3) Incorporate prevention and control of other respiratory infectious diseases such as influenza, COVID-19, respiratory syncytial virus and adenovirus, and intelligently monitor by integrating multi-channel data to achieve the goal of co-prevention and control of multiple diseases.

[Understanding the behavioural and social drivers of vaccine uptake: introduction and implications of World Health Organization Position Paper, 2022].

On May 20, 2022, World Health Organization (WHO) Position Paper on Understanding the Behavioural and Social Drivers of Vaccine Uptake (BeSD) was published. This review introduced the BeSD toolkit, interventions to increase vaccine uptake, and offered WHO's position and recommendation. Based on immunization practice, this position paper had some implications for improving the vaccination coverage in China: (1) To promote the BeSD toolkit localization; (2) To integrate the measurement and monitoring of BeSD into multisectoral routine efforts; (3) To enhance the diversity and professionalization of immunization practitioners; (4) To design and carry out implementation research scientifically.

[Research on the interaction between COVID-19 and influenza].

Since the global pandemic of COVID-19, different countries have implemented various prevention and control measures, which has affected the epidemic characteristics of respiratory infectious diseases such as influenza. From 2020 to 2021, the level of influenza activity was relatively low, but it is necessary to be alert that with the adjustment of national prevention and control measures, influenza may have a relatively strong epidemic rebound. In order to deal with influenza epidemic, experts were organized to publish a series of influenza studies in this issue, suggesting that influenza prevention and control cannot be underestimated during the COVID-19 pandemic. It is suggested to carry out research on the interaction between COVID-19 and influenza to explore the epidemic characteristics of the disease, develop new technologies and tools to improve the efficiency of monitoring and early warning, identify obstacles to vaccination, promote the scientific implementation of intervention measures, and achieve joint prevention and control of multiple diseases.

[Strengthen evaluation of vaccine effectiveness to facilitate scientific and targeted prevention and control of the COVID-19 pandemic].

The COVID-19 continues to spread throughout the world, and local clusters and outbreaks related to overseas imports have occurred in many places in China. Vaccination against COVID-19 is one of the most effective tools to prevent disease, severe illness and death. For vaccines developed and used by China, it is particularly important for scientific and targeted prevention and control to study different outbreak scenarios, to conduct in-depth real-world research on SARS-CoV-2 variants, and to further promote vaccine development and technical reserves. This article commented the effectiveness of COVID-19 vaccine, and prospected the future research on vaccine efficacy, immunization strategy and vaccine development, which provided evidence for optimizing vaccination strategy.

[Research progress on early warning model of influenza].

Influenza is an acute respiratory infectious disease caused by influenza virus. It usually exhibits seasonal transmission, but the novel influenza strain can lead to a pandemic with severe human health and socioeconomic consequences. Early warning of influenza epidemic is an important strategy and means for influenza prevention and control. On the basis of reviewing the main influenza surveillance and early warning systems, this study summarizes the principles, applications, advantages and disadvantages, and development prospects of common influenza early warning models, in order to provide reference for research and application of early warning technology for influenza and other acute respiratory infectious diseases.

[Thoughts and suggestions on co-administration of seasonal influenza vaccine and COVID-19 vaccine].

In the context of the global pandemic of COVID-19, the epidemic intensity, epidemic characteristics and infection risk of influenza have presented new features. COVID-19 and influenza have simultaneously emerged in many regions of the world. COVID-19 and influenza are similar in terms of transmission mode, clinical symptoms and other aspects. There are also similarities in the mechanism of influenza virus and novel coronavirus on cells. At the same time, it is feasible and significant to do a good job in the prevention and control of COVID-19 and influenza. This paper discusses the relevant strategies and measures for the joint prevention and control of influenza and novel coronavirus from the aspects of influenza vaccination to prevent co-infection, simultaneous vaccination of influenza vaccine and novel coronavirus vaccine, etc., and puts forward corresponding thoughts and suggestions, in order to provide scientific support for the formulation of strategies on seasonal influenza vaccine and novel coronavirus vaccination.

[Consideration on implementation of co-administration of Seasonal Influenza and COVID-19 vaccines during pandemic in China].

Influenza is an infectious respiratory disease caused by the influenza viruses. Older people, infants and people with underlying medical conditions could have a higher risk of severe influenza symptoms and complications. The co-infection of Coronavirus Diseases 2019 (COVID-19) with influenza viruses could lead to the complication of prevention, diagnosis, control, treatment, and recovery of COVID-19. Influenza vaccine and COVID-19 vaccine overlapped in target populations, vaccination time, and inoculation units. Although there was insufficient evidence on the immunogenicity and safety of co-administration of influenza vaccine and COVID-19 vaccine, World Health Organization and some countries recommended co-administration of inactivated influenza vaccine and COVID-19 vaccine. This review summarized domestic and international vaccination policies and research progress, and put forward corresponding suggestions in order to provide scientific support for the formulation of vaccination strategy on seasonal influenza vaccine and COVID-19 vaccine.

[Promoting influenza vaccination during 2021-2022 season from the perspective of population medicine].

The lower temperature in autumn-winter provides favorable conditions for the survival and spread of respiratory infectious diseases such as the corona virus disease 2019 (COVID-19) and influenza. It is likely that there will be a co-circulation of respiratory pathogens such as SARS-CoV-2 and influenza. In order to promote the prevention and control of influenza and the application of influenza vaccination during the COVID-19 pandemic in China, we separately discussed the risk of influenza epidemic in the 2021-2022 season, the influenza vaccination policies, and advocate influenza vaccination during the COVID-19 pandemic from the perspective of population medicine. We appeal that COVID-19 vaccination cannot delay the normal delivery of other vaccines in the national immunization programs and non-Expanded Program on Immunization (EPI) vaccines. Promoting influenza vaccination policies and improving immunization service convenience are necessary for increasing influenza vaccine coverage, protecting public health and assisting COVID-19 response.

[Promote multidisciplinary integration, and strengthen capacities on prevention, control and pandemic preparedness of influenza].

Series of the studies and consensus on the basic research on seasonal and animal influenza virus, clinical characteristics of patients with pneumonia caused by influenza A (H1N1) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disease burden of influenza, and promotion of influenza vaccination for the elderly were published in this special issue, aiming to describe the feature of influenza virological and clinical characteristics, health and economic burden, and vaccination. These researches emphasized the importance of the integration between basic medicine, clinical medicine, public health and preventive medicine in the prevention and control of infectious diseases. Based on the concept of population medicine, promoting the integration of multidisciplinary and strengthening prevention, control and pandemic preparedness on influenza, corona virus disease 2019 and other infectious diseases, could consolidate the foundation of surveillance and early warning, prevention and control, diagnosis and treatment of emerging infectious diseases, as well as improve the ability of emergency preparedness for public health events.

[Financing strategies and cost estimates of influenza vaccination for the elderly in China: explore a multi-party co-payment mechanism].

The disease burden and economic burden of seasonal influenza is substantial in China, and the Coronavirus disease 2019 (COVID-19) pandemic has brought new challenges to the prevention and control of influenza. As a priority group of influenza vaccination, the elderly are at higher risk of influenza-associated severe symptoms and deaths, and they are more price-sensitive vaccine users with better cost-effectiveness of vaccination program. Therefore, a reasonable financing mechanism of influenza vaccination should be designed for the elderly to increase their vaccination rate. This study proposes three financing strategies of influenza vaccination for the elderly in China, trying to explore the distribution of vaccination costs among individuals, central government and local governments under different financing strategies, including the individual-central-local mechanism (strategy 1), the central-local mechanism (strategy 2), and the local payment mechanism (strategy 3). Strategy 1 is feasible and sustainable for most regions in the short term. Strategy 2 is conducive to further increasing the vaccine coverage rate of the elderly. Strategy 3 encourages local fiscal payments to help relieve the financial pressure of the central government. The results revealed a relatively heavy financial burden of influenza vaccination for the elderly, and it is recommended to promote the development of a multiparty co-payment mechanism gradually based on local conditions.